Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy

Neurology

Volumn 79, Issue 2, 2012, Pages 159-162

  Bello, Luca ^a   Piva, Luisa ^a   Barp, Andrea ^a   Taglia, Antonella ^b   Picillo, Esther ^b   Vasco, Gessica ^c   Pane, Marika ^c   Previtali, Stefano C ^d   Torrente, Yvan ^e   Gazzerro, Elisabetta ^f   Motta, Maria Chiara ^g   Grieco, Gaetano S ^h   Napolitano, Sara ^d   Magri, Francesca ^e   D'Amico, Adele ⁱ   Astrea, Guja ^j   Messina, Sonia ^k   Sframeli, Maria ^k   Vita, Gian Luca ^k   Boffi, Patrizia ^l   Mongini, Tiziana ^l   Ferlini, Alessandra ^m   Gualandi, Francesca ^m   Soraru, Gianni ^a   Ermani, Mario ^a   Vita, Giuseppe ^k   Battini, Roberta ^j   Bertini, Enrico ⁱ   Comi, Giacomo P ^e   Berardinelli, Angela ^g   Minetti, Carlo ^f   Bruno, Claudio ^f   Mercuri, Eugenio ^c   Politano, Luisa ^b   Angelini, Corrado ^a   Hoffman, Eric P ⁿ   Pegoraro, Elena ^a   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f G GASLINI INSTITUTE   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

ⁱ BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^j DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^k UNIVERSITY OF MESSINA   (Italy)

^l UNIVERSITY OF TURIN   (Italy)

^m UNIVERSITY OF FERRARA   (Italy)

ⁿ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; LOSARTAN; OSTEOPONTIN; PREDNISOLONE;

ADULT; ALLELE; AMBULATORY MONITORING; ARTICLE; CHILD; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEROID THERAPY; WALKING;

EID: 84866252725     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31825f04ea     Document Type: Article

References (9)

1. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscl Thromb Vasc Biol 2007;27: 2302-2309.
2. Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol 2008;40:2303-2314.
3. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009;119:1583-1594.
4. Pegoraro E, Hoffman EP, Piva L, et al. SPP1 genotype is a determinant of disease severita in Duchenne muscular dystrophy. Neurology 2011;76:219 -226.
5. Nelson SF, Griggs RC. Predicting the severita of Duchenne muscular dystrophy: implications for treatment. Neurology 2011;76:208 -209.
6. Mazzone ES, Messina S, Vasco G, et al. Reliabilita of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009;19:458-461.
7. Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010;20:712-716.
8. Mazzone E, Vasco G, Sormani MP, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 2011;77:250 -256.
9. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010;41:500- 510.